Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Auxiliary glioblastoma diagnosis and prognostic evaluation kit based on IFI30 gene and using method thereof

A technology for glioblastoma and auxiliary diagnosis, which is applied in the direction of biochemical equipment and methods, microbiological measurement/testing, etc., can solve the problems that the expression status and prognosis indicators have not been reported, and achieve objective patient prognosis and survival time The effect of reducing and objectively judging

Inactive Publication Date: 2017-12-15
THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

IFI30 has been partially reported in melanoma and breast cancer, but its expression and prognosis indicators in glioma have not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Auxiliary glioblastoma diagnosis and prognostic evaluation kit based on IFI30 gene and using method thereof
  • Auxiliary glioblastoma diagnosis and prognostic evaluation kit based on IFI30 gene and using method thereof
  • Auxiliary glioblastoma diagnosis and prognostic evaluation kit based on IFI30 gene and using method thereof

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment

[0035] The experimental methods in the following examples are conventional methods unless otherwise specified, and the involved experimental reagents and materials are conventional biochemical reagents and materials unless otherwise specified.

[0036] 1. TCGA database comparison of IFI30 differential expression in LGG and GBM

[0037] The Cancer Genome Atlas (TCGA) project team was originally composed of the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI), and developed into A very large data research platform. As one of the earliest tumors studied, low-grade glioma (LGG) and glioblastoma (GBM) have a large number of comprehensive data results. The LGG and GBM data in TCGA come from (https: / / genome-cancer.ucsc.edu), in which LGG included 530 tumor samples, and GBM included 167 samples. The results of IFI30 gene transcription level are from the RNA-seq results of the Illumina HiSeq sequencing platform. figure 1 It is the expression o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of detection kits, and particularly relates to an auxiliary glioblastoma diagnosis and prognostic evaluation kit based on an IFI30 gene and a using method thereof. The kit comprises a PCR primer pair which amplifies the IFI30 gene and a PCR primer pair which amplifies a housekeeping gene GAPDH. The kit firstly discovers that the IFI30 gene has obvious difference on the transcriptional expression level in LGG and GBM, meanwhile the expression level of the IFI30 gene can well judge the prognosis of a glioblastoma patient, and the index, which can be used for independently judging the prognosis of glioblastoma, of the IFI300 gene is determined through a Cox multi-factor regression analysis, that is, the expression condition of the IFI300 gene transcriptional level is detected so that the kit can diagnose the malignant degree of the glioblastoma patient and predict the prognosis condition of the patient.

Description

technical field [0001] The invention belongs to the technical field of detection kits, and in particular relates to a glioblastoma auxiliary diagnosis and prognosis evaluation kit based on IFI30 gene and a use method thereof. Background technique [0002] Glioblastoma is the most malignant and most common primary brain tumor, accounting for about 50% of central nervous system tumors. Although a comprehensive program based on surgery combined with radiation and chemotherapy has become a treatment guideline, the prognosis of glioblastoma patients has not been significantly improved, and the average survival time is only 12 to 15 months. Patients with low-grade glioma (LGG) will develop into high-grade glioma (GBM) after a long or short period of time. At present, the commonly used methods to distinguish low-grade gliomas from high-grade gliomas mainly rely on histopathological diagnosis, but the results of pathological diagnosis have certain human factors and are somewhat unr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68
CPCC12Q1/6886C12Q2600/118C12Q2600/158
Inventor 张毅张超奇张震刘莎莎李砺锋王乐何谦益宋梦佳沈志博赵启泰
Owner THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com